# A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma

> **NCT04813354** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 114 (actual)

## Conditions studied

- Asthma

## Interventions

- **DEVICE:** ELLIPTA
- **DEVICE:** BREEZHALER

## Key facts

- **NCT ID:** NCT04813354
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-14
- **Primary completion:** 2021-07-08
- **Final completion:** 2021-07-08
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04813354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04813354, "A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04813354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*